Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies.
OBJECTIVE
The purpose of this study is to evaluate the influence of follicle-stimulating hormone receptor (FSHR) Asn680Ser polymorphism on the ovarian response to exogenous follicle-stimulating hormone (FSH) and clinical outcomes in women undergoing controlled ovarian hyperstimulation (COH).


METHODS
A database search was conducted to identify the eligible studies that investigated the effect of FSHR Asn680Ser polymorphism on ovarian response and clinical outcomes. A pooled analysis was performed with the odds ratio (OR) or weighted mean difference (WMD) and their respective 95 % confidence interval (CI) by the STATA software with random effects model.


RESULTS
Sixteen cohort studies comprising a total of 4287 subjects were included. The number of retrieved oocytes was significantly fewer in subjects with the SS genotype at position 680, compared to subjects with the NN or NS genotype (WMD = -1.36, 95 % CI = -1.85 to -0.87). Lack of association was detected between the genotypes (SS genotype vs. NN or NS genotype) and clinical outcomes such as exogenous FSH dose (WMD = 98.96 IU, 95 % CI = -22.33 to 220.24), poor response (OR = 1.08, 95 % CI = 0.71-1.64), ovarian hyperstimulation syndrome (OHSS) (OR = 1.58, 95 % CI = 0.41-6.07), and clinical pregnancy rate (OR = 1.10, 95 % CI = 0.86-1.40). However, poor ovarian response and number of retrieved oocytes were significantly influenced by the Asn680Ser polymorphism in the Asian subjects. In addition, no publication bias was detected.


CONCLUSIONS
FSHR Asn680Ser polymorphism might be a significant biomarker for predicting the number of retrieved oocytes and poor response, especially in Asian subjects. Other outcomes such as exogenous FSH dose, OHSS, and pregnancy rate were not influenced by FSHR Asn680Ser polymorphism.
Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.
Huilin
H
Tang
Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.
Yingying
Y
Yan
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Tiansheng
T
Wang
Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.
Ting
T
Zhang
Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.
Weilong
W
Shi
Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.
Rong
R
Fan
Pharmacy department of Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Yao
Y
Yao
Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China. zhaisuodi@163.com.
Suodi
S
Zhai
D015331:Cohort Studies; D005260:Female; D056726:Genetic Association Studies; D005819:Genetic Markers; D005838:Genotype; D006801:Humans; D010053:Ovary / Q000187:drug effects; D010062:Ovulation Induction; D011110:Polymorphism, Genetic; D011247:Pregnancy; D018873:Pregnancy Rate; D011962:Receptors, FSH / Q000235:genetics*; D012044:Regression Analysis
D005819:Genetic Markers; D011962:Receptors, FSH
FSHR; Genetic polymorphism; Meta-analysis; Ovarian response